6Schalkwijk DC,Poland W.Plasma concentration of Creactive protein is increased in type 1 diabetic patients withoutclinical macroangiopathy and correlates with markers of endothelial dysfunction:evidence for chronic inflammation[J].Diabetologia,1999,42(3):351-357
7Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease [J]. Circulation, 2001,103:1813-1818.
8Freeman D J, Norrie J, Caslake MJ. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study [ J ]. Diabetes, 2002, 51 : 1596-1600.
3GALKINA E,LEY K.Leukocyte recruitment and vascular injury in diabetic nephropathy[J].J Am Soc Nephrol,2006,17(2):368-377.
4KIKUCHI Y,IKEE R,HEMMI N,et al.Fractalkine and its receptor,CX3CR1,upregulation in streptozotocin-induced diabetic kidneys[J].Nephron Exp Nephrol,2004,97(1):e17-e25.
5KIKUCHI Y,IMAKIIRE T,HYODO T,et al.Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli[J].Nephrol Dial Transplant,2005,20(12):2690-2696.
6ARONSON D,BARTHA P,ZINDER O,et al.Association between fasting glucose and C-reactive protein in middle-aged subjects[J].Diabet Med,2004,21(1):39-44.
7Mora C, Navarro JF. The role of inflammation as pathogenic factor in the development of renal disease in diabetes [J]. Curr Diab Rep,2005,5(6) :399-401.
8American Diabetes Association. Position statement : diabetic nephropathy [J]. Diabetes Care, 1998,21 ( 1 ) : 50.
9Wang N,Fan Y,Ni P,et al. High glucose effect on the role of CD146 in human proximal tubular epithelial cells in vitro [J].J Nephrol,2008,21(6):931-940.
10Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin Ⅱ in diabetic nephropathy[J].Kidney Int Suppl,2000, 77(1) :93-98.
